Using AI to predict eye treatment for diabetic swelling
Part of Eyes & vision clinical trials.
This study uses artificial intelligence to help predict how your diabetic eye swelling (macular edema) will respond to treatment. You'll help researchers understand if AI can better guide treatment decisions for people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetic macular edema (swelling in the back of the eye from diabetes) that has never been treated before
- Your eye swelling measures at least 350 microns thick on a special eye imaging scan (OCT)
- Your vision is between 20/32 and 20/230 on a standard eye chart
- You have not had any previous eye injections, laser treatment, or steroid injections for your macular edema
- You do not have other eye diseases that could cause vision loss or affect the swelling in your macula
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This early-phase trial tests a new implant (EC-104) that goes inside the eye to treat diabetic macular edema (DME), a condition that causes blurry vision from fluid buildup. The implant slowly releases medicine over time, and the study will see if it is safe and helpful for people with DME.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.